DAPAGLIFLOZIN VERSUS SACUBITRIL-VALSARTAN FOR HEART FAILURE WITH MILDLY REDUCED OR PRESERVED EJECTION FRACTION

被引：0
|
作者：
Arbel, Ronen [1 ]
Oberoi, Mansi [1 ]
Alnsasra, Hilmi [1 ]
机构：
[1] Univ Nebraska Med Ctr, Omaha, NE USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2024年 / 83卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1404-129
引用
收藏
页码：628 / 628
页数：1
相关论文
共 50 条
  • [31] The effects of Sacubitril-Valsartan on ICD indication in patients with heart failure with reduced ejection fraction.
    Mariana Tinoco, M.
    Cardoso, F.
    Dias, G.
    Pereira, T.
    Faria, B.
    Almeida, F.
    Leite, S.
    Lourenco, A.
    EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 : 112 - 113
  • [32] Changing the treatment of heart failure with reduced ejection fraction:clinical use of sacubitril-valsartan combination
    Edgardo Kaplinsky
    Journal of Geriatric Cardiology, 2016, 13 (11) : 914 - 923
  • [33] The Effect of Sacubitril-Valsartan on Ventricular Arrhythmia Burden in Patients With Heart Failure With Reduced Ejection Fraction
    Medeiros, Paulo
    Coelho, Claudia
    Costa-Oliveira, Catia
    Rocha, Sergia
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (02)
  • [34] Effects of sacubitril-valsartan on central and obstructive apneas in heart failure patients with reduced ejection fraction
    Wang, Youmeng
    Branco, Roberto Fernandes
    Salanitro, Matthew
    Penzel, Thomas
    Schobel, Christoph
    SLEEP AND BREATHING, 2023, 27 (01) : 283 - 289
  • [35] Adoption of Sacubitril/Valsartan Among Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The Get With The Guidelines-Heart Failure Registry
    Pierce, Jacob B. B.
    Li, Zhen
    Greiner, Melissa A. A.
    Lippmann, Steven J. J.
    Hardy, N. Chantelle
    Shen, Xian
    Stampehl, Mark
    Mentz, Robert J. J.
    Allen, Larry A. A.
    Peterson, Pamela N. N.
    Fonarow, Gregg C. C.
    O'Brien, Emily C. C.
    Greene, Stephen J. J.
    CIRCULATION-HEART FAILURE, 2023, 16 (01) : E010176
  • [36] Impact of Sacubitril-Valsartan Treatment on Diastolic Function in Patients with Heart Failure and Reduced Ejection Fraction
    Pericas, Pere
    Mas-Llado, Caterina
    Ramis-Barcelo, Maria Francisca
    Valadron, Isabel
    Noris Mora, Marta
    Pasamar Marquez, Lucia
    Gonzalez Colino, Rosa
    Forteza Alberti, Jose Francisco
    Peral Disdier, Vicente
    Rossello, Xavier
    HIGH BLOOD PRESSURE & CARDIOVASCULAR PREVENTION, 2021, 28 (02) : 167 - 175
  • [37] PARAGON-HF - considerations for potential use of sacubitril-valsartan in real-world heart failure with mildly reduced ejection fraction
    Lund, Lars H.
    Savarese, Gianluigi
    JOURNAL OF CARDIAC FAILURE, 2019, 25 (12) : 1012 - 1013
  • [38] Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction Insights From PARAGON-HF
    McMurray, John J., V
    Jackson, Alice M.
    Lam, Carolyn S. P.
    Redfield, Margaret M.
    Anand, Inder S.
    Ge, Junbo
    Lefkowitz, Marty P.
    Maggioni, Aldo P.
    Martinez, Felipe
    Packer, Milton
    Pfeffer, Marc A.
    Pieske, Burkert
    Rizkala, Adel R.
    Sabarwal, Shalini, V
    Shah, Amil M.
    Shah, Sanjiv J.
    Shi, Victor C.
    van Veldhuisen, Dirk J.
    Zannad, Faiez
    Zile, Michael R.
    Cikes, Maja
    Goncalvesova, Eva
    Katova, Tzvetana
    Kosztin, Anamaria
    Lelonek, Malgorzata
    Sweitzer, Nancy
    Vardeny, Orly
    Claggett, Brian
    Jhund, Pardeep S.
    Solomon, Scott D.
    CIRCULATION, 2020, 141 (05) : 338 - 351
  • [39] Use of Sacubitril/Valsartan in heart failure with reduced ejection fraction
    吴利强
    冯慧婷
    冯慧娟
    South China Journal of Cardiology, 2019, 20 (04) : 252 - 257
  • [40] Sacubitril/valsartan in an experimental model of heart failure with preserved ejection fraction
    De Angelis, A.
    Cappetta, D.
    Telesca, M.
    Bellocchio, G.
    Urbanek, K.
    Berrino, L.
    CARDIOVASCULAR RESEARCH, 2022, 118 (SUPPL 1)
12345